Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$2.79 - $6.27 $139 - $313
50 Added 0.36%
13,889 $73,000
Q4 2022

Feb 10, 2023

SELL
$2.61 - $4.41 $4,058 - $6,857
-1,555 Reduced 10.1%
13,839 $38,000
Q3 2022

Nov 03, 2022

BUY
$4.09 - $6.5 $62,961 - $100,061
15,394 New
15,394 $64,000
Q2 2021

Aug 04, 2021

SELL
$13.43 - $19.16 $350,294 - $499,750
-26,083 Closed
0 $0
Q1 2021

Apr 30, 2021

BUY
$15.82 - $22.11 $39,281 - $54,899
2,483 Added 10.52%
26,083 $428,000
Q4 2020

Jan 29, 2021

BUY
$7.91 - $22.95 $39,550 - $114,750
5,000 Added 26.88%
23,600 $489,000
Q3 2020

Nov 05, 2020

BUY
$7.36 - $9.87 $136,896 - $183,582
18,600 New
18,600 $142,000
Q1 2020

May 05, 2020

SELL
$3.95 - $7.4 $73,916 - $138,476
-18,713 Closed
0 $0
Q4 2019

Jan 30, 2020

BUY
$2.57 - $4.73 $5,944 - $10,940
2,313 Added 14.1%
18,713 $74,000
Q3 2019

Nov 01, 2019

BUY
$3.04 - $5.32 $13,680 - $23,940
4,500 Added 37.82%
16,400 $50,000
Q2 2019

Jul 26, 2019

BUY
$2.46 - $4.52 $29,274 - $53,787
11,900 New
11,900 $52,000
Q4 2017

Jan 17, 2018

SELL
$3.73 - $6.37 $54,458 - $93,002
-14,600 Closed
0 $0
Q3 2017

Oct 17, 2017

BUY
$5.28 - $6.88 $77,088 - $100,448
14,600
14,600 $90,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $668M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.